Diabetes and risk of infections with immunomodulator therapy in inflammatory bowel diseases

BACKGROUND: Infections are an important concern in patients using immunosuppressive therapy for their inflammatory bowel disease (IBD). Diabetes affects nearly 10% of Americans. Whether it confers an additional risk with immunosuppression in IBD has not been examined previously. AIM: To examine the...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Aliment Pharmacol Ther
Glavni autori: Ananthakrishnan, Ashwin N., Cagan, Andrew, Cai, Tianxi, Gainer, Vivian S., Shaw, Stanley Y, Churchill, Susanne, Karlson, Elizabeth W., Murphy, Shawn N., Kohane, Isaac, Liao, Katherine P.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4420684/
https://ncbi.nlm.nih.gov/pubmed/25864945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.13195
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items